TY - JOUR
T1 - Cost-effectiveness and public health impact of typhoid conjugate vaccine introduction strategies in Bangladesh
AU - Weyant, Christopher
AU - Hooda, Yogesh
AU - Munira, Sira Jam
AU - Lo, Nathan C.
AU - Ryckman, Theresa
AU - Tanmoy, Arif M.
AU - Kanon, Naito
AU - Seidman, Jessica C.
AU - Garrett, Denise
AU - Saha, Samir K.
AU - Goldhaber-Fiebert, Jeremy D.
AU - Saha, Senjuti
AU - Andrews, Jason R.
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2024/4/19
Y1 - 2024/4/19
N2 - Purpose: Typhoid fever causes substantial morbidity and mortality in Bangladesh. The government of Bangladesh plans to introduce typhoid conjugate vaccines (TCV) in its expanded program on immunization (EPI) schedule. However, the optimal introduction strategy in addition to the costs and benefits of such a program are unclear. Methods: We extended an existing mathematical model of typhoid transmission to integrate cost data, clinical incidence data, and recently conducted serosurveys in urban, semi-urban, and rural areas. In our primary analysis, we evaluated the status quo (i.e., no vaccination) and eight vaccine introduction strategies including routine and 1-time campaign strategies, which differed by age groups targeted and geographic focus. Model outcomes included clinical incidence, seroincidence, deaths, costs, disability-adjusted life years (DALYs), and incremental cost-effectiveness ratios (ICERs) for each strategy. We adopted a societal perspective, 10-year model time horizon, and 3 % annual discount rate. We performed probabilistic, one-way, and scenario sensitivity analyses including adopting a healthcare perspective and alternate model time horizons. Results: We projected that all TCV strategies would be cost saving compared to the status quo. The preferred strategy was a nationwide introduction of TCV at 9–12 months of age with a single catch-up campaign for children ages 1–15, which was cost saving compared to all other strategies and the status quo. In the 10 years following implementation, we projected this strategy would avert 3.77 million cases (95 % CrI: 2.60 – 5.18), 11.31 thousand deaths (95 % CrI: 3.77 – 23.60), and save $172.35 million (95 % CrI: −14.29 – 460.59) compared to the status quo. Our findings were broadly robust to changes in parameter values and willingness-to-pay thresholds. Conclusions: We projected that nationwide TCV introduction with a catch-up campaign would substantially reduce typhoid incidence and very likely be cost saving in Bangladesh.
AB - Purpose: Typhoid fever causes substantial morbidity and mortality in Bangladesh. The government of Bangladesh plans to introduce typhoid conjugate vaccines (TCV) in its expanded program on immunization (EPI) schedule. However, the optimal introduction strategy in addition to the costs and benefits of such a program are unclear. Methods: We extended an existing mathematical model of typhoid transmission to integrate cost data, clinical incidence data, and recently conducted serosurveys in urban, semi-urban, and rural areas. In our primary analysis, we evaluated the status quo (i.e., no vaccination) and eight vaccine introduction strategies including routine and 1-time campaign strategies, which differed by age groups targeted and geographic focus. Model outcomes included clinical incidence, seroincidence, deaths, costs, disability-adjusted life years (DALYs), and incremental cost-effectiveness ratios (ICERs) for each strategy. We adopted a societal perspective, 10-year model time horizon, and 3 % annual discount rate. We performed probabilistic, one-way, and scenario sensitivity analyses including adopting a healthcare perspective and alternate model time horizons. Results: We projected that all TCV strategies would be cost saving compared to the status quo. The preferred strategy was a nationwide introduction of TCV at 9–12 months of age with a single catch-up campaign for children ages 1–15, which was cost saving compared to all other strategies and the status quo. In the 10 years following implementation, we projected this strategy would avert 3.77 million cases (95 % CrI: 2.60 – 5.18), 11.31 thousand deaths (95 % CrI: 3.77 – 23.60), and save $172.35 million (95 % CrI: −14.29 – 460.59) compared to the status quo. Our findings were broadly robust to changes in parameter values and willingness-to-pay thresholds. Conclusions: We projected that nationwide TCV introduction with a catch-up campaign would substantially reduce typhoid incidence and very likely be cost saving in Bangladesh.
KW - Bangladesh
KW - Cost-effectiveness
KW - Enteric fever
KW - Model
KW - Seroincidence
KW - Typhoid
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=85189078646&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85189078646&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2024.03.035
DO - 10.1016/j.vaccine.2024.03.035
M3 - Article
C2 - 38531727
AN - SCOPUS:85189078646
SN - 0264-410X
VL - 42
SP - 2867
EP - 2876
JO - Vaccine
JF - Vaccine
IS - 11
ER -